(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 240.48% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.11%.
Roivant Sciences's revenue in 2026 is $13,310,000.On average, 12 Wall Street analysts forecast ROIV's revenue for 2026 to be $7,265,797,943, with the lowest ROIV revenue forecast at $5,400,680,780, and the highest ROIV revenue forecast at $9,543,874,662. On average, 12 Wall Street analysts forecast ROIV's revenue for 2027 to be $50,485,558,204, with the lowest ROIV revenue forecast at $9,202,485,220, and the highest ROIV revenue forecast at $233,869,660,537.
In 2028, ROIV is forecast to generate $443,734,704,940 in revenue, with the lowest revenue forecast at $142,531,881,434 and the highest revenue forecast at $828,066,215,509.